Novo Holdings would like to congratulate our portfolio company Edgewise Therapeutics, Inc., (NASDAQ: EWTX) on their recent IPO, a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders.

For further information, please find the full statement here.